Inactive Instrument

Freeline Therapeutics Holdings plc

FRLN

US35655L2060

Biotechnology & Medical Research

Freeline Therapeutics Holdings plc Appoints Henning R. Stennicke as Chief Scientific Officer

February 03, 2022 at 05:30 pm IST

Freeline Therapeutics Holdings plc announced the expansion of its executive leadership team with the appointment of Henning R. Stennicke, PhD, as Chief Scientific Officer (CSO).

Latest news about Freeline Therapeutics Holdings plc

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting	09/05	CI
Syncona’s Takeover of Freeline Therapeutics Becomes Effective	20/02	MT
Freeline Therapeutics Holdings plc Announces Resignation of Julia Gregory, Martin Andrews, Jeffrey Chodakewitz, Colin Love and Paul Schneider from the Board	20/02	CI
Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index	20/02	CI
Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc.	20/02	CI
Freeline shareholders approve Syncona acquisition	12/02	AN
Freeline Therapeutics' Shareholders Approve Acquisition by Syncona	12/02	MT
Syncona says Freeline trial for Gaucher disease treatment positive	19/01	AN
European Equities Traded in the US as American Depositary Receipts Gain Friday	22/12	MT
Freeline Therapeutics Holdings plc Reports Earnings Results for the Nine Months Ended September 30, 2023	01/12	CI
HC Wainwright Downgrades Freeline Therapeutics to Neutral From Buy, Adjusts Price Target to $6.50 From $15	28/11	MT
Sector Update: Health Care Stocks Advance Late Afternoon	23/11	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23/11	MT
FTSE 100 Closes Down 0.17% After Autumn Statement	22/11	DJ
Syncona agrees to buyout deal with Freeline Therapeutics	22/11	AN
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday	22/11	MT
Sector Update: Health Care	22/11	MT
Syncona to Take Over Freeline Therapeutics	22/11	MT
Freeline Therapeutics to be Acquired by Syncona for $28.3 Million	22/11	MT
ADRs End Higher, Yoshitsu Co. Ltd. Climbs 19.2%	11/11	DJ
ADRs Advance; Freeline Therapeutics Holdings Climbs 30%	04/11	DJ
Freeline Therapeutics Holdings plc Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate	25/23/25	CI
Freeline Therapeutics Says FLT201 Showed 'Substantial' Drop in Gaucher Disease Biomarker in First Patient of Phase 1/2 Study	25/23/25	MT
FTSE 100 Closes Down 1.1% on Middle East Tensions	18/23/18	DJ
Wedbush Downgrades Freeline Therapeutics to Neutral From Outperform, Cuts Price Target to $5 From $8	18/23/18	MT

Chart Freeline Therapeutics Holdings plc

Duration

Period

Chart Freeline Therapeutics Holdings plc

More charts

Freeline Therapeutics Holdings plc is a United Kingdom-based clinical-stage biotechnology company. The Company is developing transformative adeno-associated virus (AAV) vector-mediated gene therapies. It is focused on improving patient lives through one-time treatments for chronic debilitating diseases. It uses its rationally designed AAV vector and capsid (AAVS3), along with promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient's bloodstream. Therapeutic AAV vectors consist of two main components, the capsid and the expression cassette (that contains the gene and the promoter). The Company is advancing clinical programs in Fabry disease and Gaucher disease Type 1. The Company's pipeline includes Fabry Disease FLT190 for the treatment of Fabry disease and Gaucher Disease FLT201 for the treatment of type 1 Gaucher disease.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	11TCr
REGENERON PHARMACEUTICALS, INC.	+11.60%	10TCr
BIONTECH SE	-4.68%	2.38TCr
ARGENX SE	-0.82%	2.17TCr
GENMAB A/S	-10.12%	1.81TCr
WUXI APPTEC CO., LTD.	-42.12%	1.63TCr
BEIGENE, LTD.	-17.47%	1.61TCr
NEUROCRINE BIOSCIENCES, INC.	+2.77%	1.38TCr
SAREPTA THERAPEUTICS, INC.	+34.58%	1.18TCr

Bio Therapeutic Drugs